EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Immunological mechanisms in steatotic liver diseases: An overview and clinical perspectives

Mengyao Yan, Shuli Man, Long Ma, Lanping Guo, Luqi Huang, Wenyuan Gao

Clinical and Molecular Hepatology · 01.10.2024 · 30 (4) · 620-648

DOI: 10.3350/cmh.2024.0315 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.10.2024. Verfasst von Mengyao Yan und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Food Nutrition and Safety, Key Laboratory of Industrial Microbiology, Ministry of Education, Tianjin Key Laboratory of Indust…. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 253 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Steatotic liver diseases (SLD) are the principal worldwide cause of cirrhosis and end-stage liver cancer, affecting nearly a quarter of the global population. SLD includes metabolic dysfunction-associated alcoholic liver disease (MetALD) and metabolic dysfunction-associated steatotic liver disease (MASLD), resulting in asymptomatic liver steatosis, fibrosis, cirrhosis and associated complications. The immune processes include gut dysbiosis, adiposeliver organ crosstalk, hepatocyte death and immune cell-mediated inflammatory processes. Notably, various immune cells such as B cells, plasma cells, dendritic cells, conventional CD4+ and CD8+ T cells, innate-like T cells, platelets, neutrophils and macrophages play vital roles in the development of MetALD and MASLD. Immunological modulations targeting hepatocyte death, inflammatory reactions and gut microbiome include N-acetylcysteine, selonsertib, F-652, prednisone, pentoxifylline, anakinra, JKB-121, HA35, obeticholic acid, probiotics, prebiotics, antibiotics and fecal microbiota transplantation. Understanding the immunological mechanisms underlying SLD is crucial for advancing clinical therapeutic strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeHumansFatty LiverDysbiosisFecal Microbiota TransplantationAnimals

Stichwörter der Autor:innen

Adipose tissueDysbiosisImmunityLiver diseases

Autor:innen und Institutionen

  • State Key Laboratory of Food Nutrition and Safety, Key Laboratory of Industrial Microbiology, Ministry of Education, Tianjin Key Laboratory of Industry Microbiology, National and Local United Engineering Lab of Metaboli…
  • National Resource Center for Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
  • Tianjin Key Laboratory for Modern Drug Delivery & High-Efficiency, School of Pharmaceutical Science and Technology, Tianjin University, Weijin Road, Tianjin, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Yan, M., Man, S., Ma, L., Guo, L., Huang, L., & Gao, W. (2024). Immunological mechanisms in steatotic liver diseases: An overview and clinical perspectives. Clinical and Molecular Hepatology, 30(4), 620-648. https://doi.org/10.3350/cmh.2024.0315

Vancouver

Yan M, Man S, Ma L, Guo L, Huang L, Gao W. Immunological mechanisms in steatotic liver diseases: An overview and clinical perspectives. Clinical and Molecular Hepatology. 2024;30(4):620-648. doi:10.3350/cmh.2024.0315

BibTeX
@article{Yan2024,
  author = {Yan, Mengyao and Man, Shuli and Ma, Long and Guo, Lanping and Huang, Luqi and Gao, Wenyuan},
  title = {Immunological mechanisms in steatotic liver diseases: An overview and clinical perspectives},
  journal = {Clinical and Molecular Hepatology},
  year = {2024},
  volume = {30},
  number = {4},
  pages = {620--648},
  doi = {10.3350/cmh.2024.0315}
}
Kostenlos starten →